Discovery of target molecules for cancer immunotherapy by genetic and bioinformatic approaches -- Current strategies for the identification of immunogenic epitopes of tumor antigens -- Current and future role of natural-killer cells in cancer immunotherapy -- The role of immune monitoring in evaluating cancer immunotherapy -- Statistical analysis of immune response assays -- DNA vaccines for cancer immunotherapy -- Dendritic cells -- Different approaches to dendritic cell-based cancer immunotherapy -- Anti-idiotype antibody vaccines for the immunotherapy of cancer -- Autologous tumor-derived heat shock protein vaccine as a new paradigm for individualized cancer therapeutics -- Tumor-reactive T-cells for adoptive immunotherapy -- T-cell adoptive immunotherapy of cancer: from translational models to clinical significance -- Retroviral-mediated gene transfer for engineering tumor-reactive T-cells -- Harnessing the potential of graft-vs-tumor -- Tumor-induced immune suppression and immune escape: mechanisms and impact on the outcome of immunotherapy of malignant disease -- The tumor microenvironment: regulation of antitumor immunity and implications for immunotherapy -- Manipulation of lymphocyte homeostasis for enhancing antitumor immunity -- Fast-lane evolution in the tumor microenvironment -- Manipulating immunological checkpoints to maximize antitumor immunity -- Interleukin-2 as cancer therapy -- Biological and clinical properties of the type 1 interferons -- Promising g [gamma]-chain cytokines for cancer immunotherapy: interleukins-7, -15, and -21 as vaccine adjuvants, growth factors -- The therapeutic use of natural-killer cells in hematological malignancies -- Antibody therapy for solid tumors -- Antibody therapy for non-Hodgkin's lymphoma -- Approaches to in vivo imaging of cancer immunotherapy -- Design issues for early-stage clinical trials for cancer vaccines -- Monoclonal antibody therapy for cancer.